Article3 Biotech2025
Functionalized nanoparticles based on β-chitosan and styrene copolymer derivative for donepezil delivery.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding charged polymer-lipid interactions in model membranes revealed by EPR and solid-state NMR: Implications for membrane protein studies.Chemistry and physics of lipids · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing a drug delivery strategy that can cross the blood-brain barrier is crucial to effective neurological treatment. In this work, a new strategy was introduced for efficient drug delivery of Donepezil based on the preparation of polyelectrolyte complexes (PEC) nanogel from β-chitosan (CS) and the prepared sulfonated styrene-maleic anhydride (S-SMA). First, low-molecular-weight SMA was prepared. Then, sulphonation of SMA was carried out. Three PEC nanoparticles were prepared by mixing three different ratios of S-SMA with β-chitosan. The structure and characteristics of the nanoparticles were thoroughly investigated. Varying S-SMA content (donated CS-S1, CS-S2, and CS-S3) for fixed a β-CS content, the surface charge and average size of the nanoparticles were tunable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.